Roquefort Therapeutics plc

LSE ROQ.L

Roquefort Therapeutics plc Gross Profit for the year ending December 31, 2023: USD 254.47 K

Roquefort Therapeutics plc Gross Profit is USD 254.47 K for the year ending December 31, 2023, a 0.00% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • Roquefort Therapeutics plc Gross Profit for the year ending December 31, 2022 was USD 0.00, a 100.00% change year over year.
  • Roquefort Therapeutics plc Gross Profit for the year ending December 31, 2021 was USD -12.65 K.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
LSE: ROQ.L

Roquefort Therapeutics plc

CEO Mr. Trevor Ajanthan Reginald
IPO Date March 22, 2021
Location United Kingdom
Headquarters Eccleston Yards
Employees 10
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

StockViz Staff

January 15, 2025

Any question? Send us an email